You are viewing the site in preview mode
Skip to main content
|
Patients n = 17
|
n (%)
|
|---|
|
Characteristics
|
|
Gender
|
|
Male
|
10 (59%)
|
|
Female
|
7 (41%)
|
|
Median age, years (range)
|
50 (26-66)
|
|
Karnofsky performance status
|
|
Median (range)
|
80 (60-100)
|
|
90-100
|
4 (24)
|
|
70-80
|
12 (71)
|
|
60
|
1 (5)
|
|
Laterality
|
|
Right
|
5 (29)
|
|
Left
|
12 (71)
|
|
Lobe
|
|
Fronto-temporal
|
5 (29)
|
|
Parieto-temporal
|
3 (18)
|
|
Frontal
|
2 (12)
|
|
Temporal
|
4 (24)
|
|
Parietal
|
1 (5)
|
|
Multilobar
|
2 (12)
|
|
Histotype
|
|
Glioblastoma multiforme
|
12 (71)
|
|
Grade III gliomas
|
5 (29)
|
|
MGMT promoter methylation status at diagnosis
|
|
Methylated
|
9 (53)
|
|
Unmethylated
|
3 (18)
|
|
Unknown
|
5 (29)
|
|
IDH1 status at diagnosis:
|
|
Mutated
|
5 (29)
|
|
Non mutated
|
3 (18)
|
|
Unknown
|
9 (53)
|
|
Surgery at recurrence
|
|
Yes
|
15 (88)
|
|
No
|
2 (12)
|
|
Chemotherapy treatment
|
|
First-line therapy
|
|
STUPP (RT/TMZ-TMZ)
|
17 (100%)
|
|
Line of BEV treatment
|
|
Second
|
4 (24)
|
|
Third
|
13 (76)
|
|
BEV treatment
|
|
Monotherapy
|
13 (76)
|
|
Combined with FTM
|
4 (24)
|
|
Median cycles received, number (range)
|
8 (2-40)
|
